Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
- Details
- Category: Novartis

Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
- Details
- Category: Novartis

Merck brand relaunched
- Details
- Category: Merck Group

Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC)
- Details
- Category: Bristol-Myers Squibb

Roche's ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis
- Details
- Category: Roche

Johnson & Johnson announces completion of Cordis divestiture to Cardinal Health
- Details
- Category: Johnson & Johnson

Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
- Details
- Category: Novartis

More Pharma News ...
- Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline
- Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care
- New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
- New Roche Esbriet data show clinical benefits of continued and long-term treatment in patients with idiopathic pulmonary fibrosis (IPF)
- Merck's Consumer Health business counts on Latin America for growth
- Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
- Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®